Strategic planning must reflect this new standard of care
Providers often indicate that youll need several shots each week although you may be able to slowly reduce shot frequency
And with more than half of the global population (51% or over 4 billion people) predicted to be either overweight or living with obesity by 2035, investment in obesity drugs is forecast to rise by a compound annual growth rate of 35%38% between 2023 and 2027.9,10 While some GLP-1 treatments currently in the pipeline are set to reach the market in oral tablet form, autoinjectors and pen injectors currently at the forefront of GLP-1 delivery will continue to deliver multiple patient benefits across this significantly expanded market segment
You can bring a larger cooler
A lesser explanation is that these drugs may interfere with the absorption of oral contraceptives, reducing their effectiveness
Quick verdict MeAgain is the best MacroFactor alternative for GLP-1 users who want food tracking connected to shots, symptoms, weight, progress, and medication context